CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Ontakdrug
Likely dose
Ontak 12 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00880360
NCT00880360Phase 2Completed
CompareCT.gov

A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy

The University of Texas Health Science Center at San Antonio·interventional·Posted Apr 13, 2009·Updated Mar 27, 2018

In Brief

A Phase 2 clinical trial evaluating Ontak for Epithelial Ovarian Cancer and 2 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2009
Enrollment StartFeb 1, 2007
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.2 years ago

Interventions

Ontakdrug

Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.